Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease.

Abstract

BACKGROUND:

Intravenous periodic Iloprost is proven effective in the treatment of Raynaud phenomenon (RP) related to connective tissue disorder (CTD). It's well known that synthetic prostaglandins are effective drugs for the treatment of pulmonary arterial hypertension (PAH), and that PAH is frequently associated with CTD.

OBJECTIVE:

The aim of the study is to evaluate in the chronic effect of cyclic intravenous Iloprost on pulmonary arterial pressure.

METHODS:

We studied 17 consecutive patients with CTD (14 systemic sclerosis, 3 mixed CTD) and RP, at the entry and after at least 6months of treatment of RP with cyclic Iloprost. On both occasions, in all patients we performed transthoracic Doppler echocardiography and we determined NT-proBNP plasma levels, NYHA functional class, 6 Minute-Walk Distance (6MWD).

RESULTS:

At follow-up (8.2±1.9months; range 6-12) mean values of pulmonary arterial systolic pressure (PASP) significantly decreased (from 32.2±9.2 to 29.2±7.6mmHg, p<0.04) and mean values of 6MWD significantly increased (from 407.5±101.5 to 448.3±89.9m, p<0.01). Moreover, we observed a significant direct correlation between PASP and NT-proBNP values and a significant inverse correlation both between NT-proBNP and 6MWD values and between PASP and 6MWD values.

CONCLUSION:

Our results suggest that cyclic intravenous Iloprost may protect against the development or worsening of PAH in patients with CTD and RP.

• Authors: Sergio Caravita, Sheng Chin Wu, Maria Beatrice Secchi, Viola Dadone, Chiara Bencini, Simona Pierini
• Journal: European journal of internal medicine (Eur J Intern Med) Vol. 22 Issue 5 Pg. 518-21 (Oct 2011) ISSN: 1879-0828 [Electronic] Netherlands
• PMID: 21925064 (Publication Type: Comparative Study, Journal Article)
• Copyright: Copyright © 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Chemical References

• Cardiovascular Agents
• Iloprost

Topics

• Adult
• Aged
• Cardiovascular Agents (administration & dosage, therapeutic use)
• Connective Tissue Diseases (complications, physiopathology)
• Dose-Response Relationship, Drug
• Familial Primary Pulmonary Hypertension
• Female
• Follow-Up Studies
• Humans
• Hypertension, Pulmonary (etiology, physiopathology, prevention & control)
• Iloprost (administration & dosage, therapeutic use)
• Infusions, Intravenous
• Male
• Middle Aged
• Pulmonary Wedge Pressure (drug effects, physiology)
• Retrospective Studies
• Time Factors
• Treatment Outcome